FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to therapy, and can be used in the treatment of postcoid syndrome. The method includes providing patients with basic therapy with antibiotics, anticoagulants and acetylsalicylic acid and the use of the antioxidant thiotriazoline in the form of 200 mg tablets twice a day for 30 days.
EFFECT: invention makes it possible to increase effectiveness of treatment, to reduce the drug load and side effects of basic therapy, to achieve an endothelioprotective effect by increasing the expression of eNOS, as well as an anti-thrombotic effect by reducing the level of D-dimer in the blood of patients under the influence of thiotriazoline.
1 cl, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HEPATOPROTECTIVE, CARDIOPROTECTIVE AND PLACENTAPROTECTIVE, UTEROLITH AND NO-MIMETIC COMBINED DRUG | 2015 |
|
RU2597785C1 |
| METHOD FOR TREATMENT OF PATIENTS WITH POST-COVID SYNDROME | 2022 |
|
RU2787802C1 |
| METHOD OF PREVENTING ENDOTHELIAL DAMAGE IN CRITICALLY ILL PATIENTS | 2023 |
|
RU2812594C1 |
| COMPOSITION POSSESSING ENDOTHELIAL PROTECTIVE, VASODILATING AND ANGIOPROTECTIVE EFFECT | 2011 |
|
RU2464019C1 |
| METHOD FOR DETERMINING THE DEGREE OF RISK OF DEVELOPING CARDIOVASCULAR COMPLICATIONS IN COVID-19 | 2021 |
|
RU2768575C1 |
| PHARMACEUTICAL COMPOSITION OF BIOFLAVONOIDS HESPERIDIN AND PINOSTROBIN POSSESSING ENDOTHELIUM PROTECTIVE, ANTICOAGULANT AND ACTOPROTECTIVE ACTION | 2014 |
|
RU2575790C2 |
| METHOD FOR CORRECTING MICROCIRCULATORY DISORDERS IN POST-COVID SYNDROME | 2022 |
|
RU2791660C1 |
| METHOD OF TREATING PATIENTS WITH CHRONIC GLOMERULONEPHRITIS COMBINED WITH CHRONIC OPISTHORCHIASIS | 2010 |
|
RU2417081C1 |
| METHOD FOR OPTIMIZING LABORATORY DIAGNOSIS OF THROMBINEMIA IN PATIENTS WITH COVID-19 INFECTION | 2022 |
|
RU2789822C1 |
| METHOD FOR DETECTING VASCULAR ENDOTHELIUM INVOLVEMENT | 2021 |
|
RU2766781C1 |
